Nektar Inks $1.85B Bristol-Myers Cancer Drug Collaboration
Nektar Therapeutics has inked a $1.85 billion cash-and-stock deal to jointly develop and manage its cancer-fighting, immuno-stimulatory therapy in combination with two Bristol-Myers Squibb cancer treatments, the companies said Wednesday....To view the full article, register now.
Already a subscriber? Click here to view full article